Skip to main content
. Author manuscript; available in PMC: 2009 Jan 17.
Published in final edited form as: Hum Gene Ther. 2006 Jan;17(1):46–54. doi: 10.1089/hum.2006.17.46

FIG. 3.

FIG. 3

CsCl gradient-purified AAV-221-IV vector corrects the hemophilia phenotype. Hemophilia B mice (F.IX-CD4 double knockout) were injected with CsCl gradient-purified AAV1, AAV2, or AAV-221-IV (1 × 1011 VG/mouse) carrying the CMV-hFIX expression cassette. (A) Time course of hFIX expression after vector injection. hFIX expression was measured by ELISA at each time point shown. The average expression levels and standard deviation are shown for each group (n = 3). (B) Activated partial thromboplastin time (aPTT, in seconds) of hemophilic mice as a function of time after intramuscular injection of CsCl-purified vectors. The average aPTT and standard deviation of each group (n = 3) are shown. The aPTT times of hemophilic mice (>60 sec) and of nonhemophilic CD4 knockout mice (35-38 sec) are indicated as horizontal dotted lines. The p value for the difference is less than 0.05.